Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00022555 · ClinicalTrials.gov registry record · Phase 1

Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma

A Phase 1 study of AIDS-related Diffuse Large Cell Lymphoma and AIDS-related Diffuse Mixed Cell Lymphoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT00022555 is a Phase 1 study of AIDS-related Diffuse Large Cell Lymphoma and AIDS-related Diffuse Mixed Cell Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00022555, a Phase 1 study of AIDS-related Diffuse Large Cell Lymphoma and AIDS-related Diffuse Mixed Cell Lymphoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Phase I trial to study the effectiveness of bryostatin 1 plus vincristine in treating patients who have recurrent or refractory lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bryostatin 1 may help vincristine kill more cancer cells by making them more sensitive to the drug

Interventions

  • DRUG bryostatin 1
  • DRUG vincristine sulfate

Study Locations (1)

Maryland

  • AIDS - Associated Malignancies Clinical Trials Consortium - Rockville

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2001-11
Phase Phase 1

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00022555

The ClinicalTrials.gov registry entry for NCT00022555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with AIDS-related Diffuse Large Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which bryostatin 1 is the first listed.

NCT00022555 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00022555 about?

NCT00022555 is a clinical study titled "Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma". Phase I trial to study the effectiveness of bryostatin 1 plus vincristine in treating patients who have recurrent or refractory lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bryostatin 1 may help vincristine kill more cancer c...

What is the current status of trial NCT00022555?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2001-11.

What conditions does trial NCT00022555 study?

This clinical trial studies the following conditions: AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma.

What interventions are being tested in trial NCT00022555?

The interventions under investigation include: bryostatin 1 (DRUG), vincristine sulfate (DRUG).

Who is sponsoring clinical trial NCT00022555?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00022555 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.